丙泊酚对前列腺癌细胞增殖及雄激素转录活性的影响及其机制

doi:10.3969/j.issn.1671-7171.2021.11.016

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1217 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of propofol on the proliferation of prostate cancer cell line (LNCaP) stimulated by dihydrotestosterone (DHT) and its mechanism. 【Methods】 LNCaP cells were divided into four groups according to the intervention mode: control group (normal saline), DHT group (10 nM DHT intervention), DHT + 10 μm propofol group (10 nM DHT + 10 μM propofol intervention) and DHT + 50 μM propofol group (10 nM DHT + 50 μM propofol intervention). Real time quantitative PCR was used to detect the levels of androgen dependent gene prostate specific antigen (PSA), FK506 binding protein 5 (FKBP5) and transmembrane protease serine 2 (TMPRSS2). MTT method was used to analyze the survival of cells in each group. Western blot was used to detect the expression of AR and hypoxia inducible factor (HIF) in cells in each group. 【Results】 Compared with the DHT group, the expression of PSA, FKBP5 and TMPRSS2 genes in the DHT+10 μM propofol group and the DHT+ 50 μM propofol group decreased significantly at 24 hours (P<0.05). Propofol exposure for 12 h and 24 h could significantly inhibit the proliferation of LNCaP cells (P<0.05), but exposure for 4 h had no significant effect. Compared with the DHT group, the expression of AR and HIF-1α protein in nucleus of the DHT + 10 μM propofol group and the DHT+50 μM propofol group were significantly lower (P<0.05). 【Conclusion】 Propofol inhibits the proliferation of LNCaP cells and AR transcriptional activity, so as to reduce the level of AR nucleoprotein.

Key words： Propofol/TU Prostatic Neoplasms /PA Cell Proliferation Androgens

Received: 16 September 2021

PACS:

R737.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Yan-an
	ZHANG Yu-ming
	ZHANG Ru
	et al

Cite this article:

JIANG Yan-an,ZHANG Yu-ming,ZHANG Ru, et al. Effects of Propofol on Proliferation and Androgen Transcriptional Activity of Prostate Cancer Cells and its Mechanism[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(11): 1659-1662.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.11.016 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I11/1659

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2] ZHAO K, LI S, WU L,et al. Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module[J].J Biol Chem,2014,289(30):20824-20835.
[3] LONERGAN P E, TINDALL D J. Androgen receptor signaling in prostate cancer development and progression[J].J Carcinog,2011,10:20.
[4] QUIGLEY C A, DE BELLIS A, MARSCHKE K B,et al. Androgen receptor defects: historical, clinical, and molecular perspectives[J].Endocr Rev,1995,16(3):271-321.
[5] GIRLING J S, WHITAKER H C, MILLS I G, et al. Pathogenesis of prostate cancer and hormone refractory prostate cancer[J].Indian J Urol,2007,23(1):35-42.
[6] HEINLEIN C A, CHANG C. Androgen receptor in prostate cancer[J].Endocr Rev,2004,25(2):276-308.
[7] BYRNE K, LEVINS K J, BUGGY D J. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis?[J].Can J Anaesth,2016,63(2):184-92.
[8] DE OLIVEIRA G S, JR AHMAD S, SCHINK J C, et al. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery[J].Reg Anesth Pain Med,2011,36(3):271-277.
[9] WIGMORE T J, MOHAMMED K, JHANJI S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: a retrospective analysis[J].Anesthesiology,2016,124(1):69-79.
[10] ZHANG D. Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer[J].Biochem Biophys Res Commun,2015,468(4):561-567.
[11] FRAGA A, RIBEIRO R, PRINCIPE P,et al. Hypoxia and prostate cancer aggressiveness: a tale with many endings[J].Clin Genitourin Cancer,2015,13(4):295-301.
[12] GRECO O, MARPLES B, JOINER M C, et al. How to overcome (and exploit) tumor hypoxia for targeted gene therapy[J].J Cell Physiol,2003,197(3):312-325.
[13] SEMENZA G L. Targeting HIF-1 for cancer therapy[J].Nat Rev Cancer,2003,3(10):721-732.
[14] DEEP G, KUMAR R, NAMBIAR D K,et al. Silibinin inhibits hypoxia-induced HIF-1alpha-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics[J].Mol Carcinog,2017,56(3):833-848.
[15] MILOSEVIC M, WARDE P, MENARD C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer[J].Clin Cancer Res,2012,18(7):2108-2114.
[16] HUANG H, BENZONANA L L, ZHAO H, et al. Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination[J].Br J Cancer,2014,111(7):1338-1349.
[17] THADANI-MULERO M, NANUS D M, GIANNAKAKOU P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus[J].Cancer Res,2012,72(18):4611-4615.
[18] DARSHAN M S, LOFTUS M S, THADANI-MULERO M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer[J].Cancer Res,2011,71(18):6019-6029.